Veramyst

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 10/13/2021
Veramyst Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

What Is Veramyst?

Veramyst Nasal Spray (fluticasone furoate) is a corticosteroid prescribed for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older. Veramyst Nasal Spray is available in generic form.

What Are Side Effects of Veramyst?

Side effects of Veramyst Nasal Spray include:

Severe allergic reaction (anaphylaxis) may occur. Tell your doctor if you have serious side effects of Veramyst Nasal Spray including:

  • severe or persistent nosebleeds,
  • pain in your nose,
  • eye pain,
  • white patches in your nose or back of your throat,
  • painful swallowing, or
  • persistent sore throat.

Dosage for Veramyst

Each Veramyst spray contains about 27.5 mcg of fluticasone furoate. Administer Veramyst Nasal Spray by the intranasal route only and keep away from the eyes.

What Drugs, Substances, or Supplements Interact with Veramyst?

Veramyst Nasal Spray may interact with conivaptan, imatinib, isoniazid, nefazodone, antibiotics, antifungals, heart or blood pressure medications, or HIV/AIDS medicines. Tell your doctor all medications and supplements you use.

Veramyst During Pregnancy or Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant while using Veramyst Nasal Spray; it is unknown if it will harm a fetus. It is unknown if Veramyst Nasal Spray passes into breast milk or if it could harm a nursing baby. Consult your doctor before breastfeeding.

Additional Information

Our Veramyst (fluticasone furoate) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Could I Be Allergic? Discover Your Allergy Triggers See Slideshow
Veramyst Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives, rash; feeling light-headed; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

  • severe or ongoing nosebleeds;
  • noisy breathing, runny nose, or crusting around your nostrils;
  • redness, sores, or white patches in your mouth or throat;
  • fever, chills, body aches;
  • blurred vision, eye pain, or seeing halos around lights;
  • any wound that will not heal; or
  • signs of a hormonal disorder--worsening tiredness or muscle weakness, feeling light-headed, nausea, vomiting.

Steroid medicine can affect growth in children. Tell your doctor if your child is not growing at a normal rate while using this medicine.

Common side effects may include:

  • minor nosebleed, burning or itching in your nose;
  • sores or white patches inside or around your nose;
  • cough, trouble breathing;
  • headache, back pain;
  • sinus pain, sore throat, fever; or
  • nausea, vomiting.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Veramyst (Fluticasone Furoate)

QUESTION

Allergies can best be described as: See Answer
Veramyst Professional Information

SIDE EFFECTS

Systemic and local corticosteroid use may result in the following:

Clinical Trials Experience

The safety data described below reflect exposure to VERAMYST Nasal Spray in 1,563 patients with seasonal or perennial allergic rhinitis in 9 controlled clinical trials of 2 to 12 weeks' duration. The data from adults and adolescents are based upon 6 clinical trials in which 768 patients with seasonal or perennial allergic rhinitis (473 females and 295 males aged 12 years and older) were treated with VERAMYST Nasal Spray 110 mcg once daily for 2 to 6 weeks. The racial distribution of adult and adolescent patients receiving VERAMYST Nasal Spray was 82% white, 5% black, and 13% other. The data from pediatric patients are based upon 3 clinical trials in which 795 children with seasonal or perennial rhinitis (352 females and 443 males aged 2 to 11 years) were treated with VERAMYST Nasal Spray 55 or 110 mcg once daily for 2 to 12 weeks. The racial distribution of pediatric patients receiving VERAMYST Nasal Spray was 75% white, 11% black, and 14% other.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adults and Adolescents Aged 12 Years and Older

Overall adverse reactions were reported with approximately the same frequency by patients treated with VERAMYST Nasal Spray and those receiving placebo. Less than 3% of patients in clinical trials discontinued treatment because of adverse reactions. The rate of withdrawal among patients receiving VERAMYST Nasal Spray was similar or lower than the rate among patients receiving placebo.

Table 1 displays the common adverse reactions ( > 1% in any patient group receiving VERAMYST Nasal Spray) that occurred more frequently in patients aged 12 years and older treated with VERAMYST Nasal Spray compared with placebo-treated patients.

Table 1: Adverse Reactions with > 1% Incidence in Controlled Clinical Trials of 2 to 6 Weeks’ Duration with VERAMYST Nasal Spray in Adult and Adolescent Patients with Seasonal or Perennial Allergic Rhinitis

Adverse Event Adult and Adolescent Patients Aged 12 Years and Older
Vehicle Placebo
(n = 774)
VERAMYST Nasal Spray 110 mcg Once Daily
(n = 768)
Headache 54 (7%) 72 (9%)
Epistaxis 32 (4%) 45 (6%)
Pharyngolaryngeal pain 8 (1%) 15 (2%)
Nasal ulceration 3 ( < 1%) 11 (1%)
Back pain 7 ( < 1%) 9 (1%)

There were no differences in the incidence of adverse reactions based on gender or race. Clinical trials did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger subjects.

Pediatric Patients Aged 2 to 11 Years

In the 3 clinical trials in pediatric patients aged 2 to < 12 years, overall adverse reactions were reported with approximately the same frequency by patients treated with VERAMYST Nasal Spray and those receiving placebo. Table 2 displays the common adverse reactions ( > 3% in any patient group receiving VERAMYST Nasal Spray), that occurred more frequently in patients aged 2 to 11 years treated with VERAMYST Nasal Spray compared with placebo-treated patients.

Table 2: Adverse Reactions with > 3% Incidence in Controlled Clinical Trials of 2 to 12 Weeks’ Duration with VERAMYST Nasal Spray in Pediatric Patients with Seasonal or Perennial Allergic Rhinitis

Adverse Event Pediatric Patients Aged 2 to < 12 Years
Vehicle Placebo
(n = 429)
VERAMYST Nasal Spray 55 mcg Once Daily
(n = 369)
VERAMYST Nasal Spray 110 mcg Once Daily
(n = 426)
Headache 31 (7%) 28 (8%) 33 (8%)
Nasopharyngitis 21 (5%) 20 (5%) 21 (5%)
Epistaxis 19 (4%) 17 (5%) 17 (4%)
Pyrexia 7 (2%) 17 (5%) 19 (4%)
Pharyngolaryngeal pain 14 (3%) 16 (4%) 12 (3%)
Cough 12 (3%) 12 (3%) 16 (4%)

There were no differences in the incidence of adverse reactions based on gender or race. Pyrexia occurred more frequently in children aged 2 to < 6 years compared with children aged 6 to < 12 years.

Long-term (52-Week) Safety Trial

In a 52-week, placebo-controlled, long-term safety trial, 605 patients (307 females and 298 males aged 12 years and older) with perennial allergic rhinitis were treated with VERAMYST Nasal Spray 110 mcg once daily for 12 months and 201 were treated with placebo nasal spray. While most adverse reactions were similar in type and rate between the treatment groups, epistaxis occurred more frequently in patients who received VERAMYST Nasal Spray (123/605, 20%) than in patients who received placebo (17/201, 8%). Epistaxis tended to be more severe in patients treated with VERAMYST Nasal Spray. All 17 reports of epistaxis that occurred in patients who received placebo were of mild intensity, while 83, 39, and 1 of the total 123 epistaxis events in patients treated with VERAMYST Nasal Spray were of mild, moderate, and severe intensity, respectively. No patient experienced a nasal septal perforation during this trial.

Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postmarketing use of VERAMYST Nasal Spray. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to fluticasone furoate or a combination of these factors.

Immune System Disorders

Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria.

Respiratory, Thoracic, and Mediastinal Disorders

Rhinalgia, nasal discomfort (including nasal burning, nasal irritation, and nasal soreness), nasal dryness, and nasal septal perforation.

Read the entire FDA prescribing information for Veramyst (Fluticasone Furoate)

© Veramyst Patient Information is supplied by Cerner Multum, Inc. and Veramyst Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors